Retatrutide builds upon this concept by targeting GLP-1, GIP, and glucagon receptors simultaneously
And were being heard
Reading Published Dose Ranges Correctly Retatrutides Phase 3 TRIUMPH-1 trial, with topline results reported by Eli Lilly in May 2026, evaluated three target doses 4mg, 9mg, and 12mg weekly with all arms starting at 2mg and escalating in steps every four weeks (2mg 4mg 6mg 9mg 12mg, depending on target arm) rather than starting at the target dose directly
Lost 28 lbs "After struggling with weight loss, I discovered Willow and highly recommend it." Ava T
Phase 3 clinical trials are ongoing, with regulatory submissions expected and potential approval in the 2026-2027 timeframe
Mazdutide takes a targeted dual-receptor approach, activating both GLP-1 and glucagon receptors simultaneously